No Data
No Data
Does Pliant Therapeutics (NASDAQ:PLRX) Have A Healthy Balance Sheet?
Express News | Aligos Therapeutics Strengthens Senior Leadership Team With the Appointment of Hardean Achneck, Md as Chief Medical Officer
Piper Sandler Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $40
Bullish on Bexo: Pliant Therapeutics' Promising IPF Treatment Backed by Strong Clinical Evidence
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential